{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:18:26Z","timestamp":1792603106577,"version":"4.5.0"},"reference-count":275,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejogrb.2023.06.021","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:32:11Z","timestamp":1687793531000},"page":"195-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Contemporary approaches in the management of uterine leiomyomas"],"prefix":"10.1016","volume":"287","author":[{"given":"Shikha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh Singh","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashasvi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2023.06.021_b0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/IJWH.S51083","article-title":"Uterine fibroids: current perspectives","volume":"6","author":"Khan","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0010","series-title":"Uterine leiomyomata","author":"Barjon","year":"2022"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0015","series-title":"Berek & Novak\u2019s gynecology","author":"Berek","year":"2020"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0025","first-page":"181","article-title":"The genetic bases of uterine fibroids; a review","volume":"12","author":"Medikare","year":"2011","journal-title":"J Reprod Infertil"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0030","doi-asserted-by":"crossref","unstructured":"Ciarmela P, Islam S, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 2011;17:772\u201390.","DOI":"10.1093\/humupd\/dmr031"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0015-0282(16)45789-4","article-title":"Uterine leiomyomata: etiology, symptomatology, and management","volume":"36","author":"Wallach","year":"1981","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2014.982246","article-title":"Contemporary management of uterine fibroids: focus on emerging medical treatments","volume":"31","author":"Singh","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/01.grf.0000211961.91616.78","article-title":"Myolysis of uterine fibroids: is there a role?","volume":"49","author":"Zupi","year":"2006","journal-title":"Clin Obstet Gynecol"},{"issue":"03","key":"10.1016\/j.ejogrb.2023.06.021_b0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1055\/s-0028-1085923","article-title":"Uterine artery embolization: a safe and effective, minimally invasive, uterine-sparing treatment option for symptomatic fibroids","volume":"25","author":"Vo","year":"2008","journal-title":"Semin Intervent Radiol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rbmo.2020.01.003","article-title":"Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids","volume":"40","author":"Khaw","year":"2020","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13645706.2019.1674337","article-title":"Laparoscopic myomectomy after or without pre-treatment with ulipristal acetate","volume":"30","author":"Mara","year":"2021","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0070","first-page":"127","article-title":"Safety and efficacy of two repeated cycles of ulipristal acetate in the management of symptomatic uterine fibroid among Indian women","volume":"20","author":"Jha","year":"2021","journal-title":"Prz Menopauzalny"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0075","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1111\/jog.14802","article-title":"Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids","volume":"47","author":"Osuga","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0080","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1210\/clinem\/dgab081","article-title":"Use of ulipristal acetate and risk of liver disease: a nationwide cohort study","volume":"106","author":"Yoon","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0085","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejogrb.2020.10.058","article-title":"A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: protocol of the MYOMEX-2 trial","volume":"256","author":"Middelkoop","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0090","doi-asserted-by":"crossref","unstructured":"\u00c1guas F, Guerreiro F, Ponte C, et al. Management of symptomatic uterine fibroids with ulipristal acetate: a retrospective, multicentric and nationwide study. J Gynecol Obstet Hum Reprod 2020;49:101862.","DOI":"10.1016\/j.jogoh.2020.101862"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/rmb2.12304","article-title":"Ulipristal acetate for Japanese women with symptomatic uterine fibroids: a double-blind, randomized, phase II dose-finding study","volume":"19","author":"Irahara","year":"2020","journal-title":"Reprod Med Biol"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/09513590.2019.1648419","article-title":"Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study","volume":"36","author":"Giarr\u00e8","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/AOG.0000000000002718","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Illingworth","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/01443615.2017.1405926","article-title":"Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital","volume":"38","author":"Woodhead","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0115","first-page":"18","article-title":"The effect of ulipristal acetate treatment on symptomatic uterine fibroids within 12-months follow-up","volume":"1","author":"Wo\u017aniak","year":"2014","journal-title":"Prz menopauzalny"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0120","first-page":"175","article-title":"Application of ulipristal acetate in female patients with uterine fibroids","volume":"35","author":"Grzechocinska","year":"2014","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0125","doi-asserted-by":"crossref","unstructured":"Whitaker LHR, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod 2017;32:531\u201343.","DOI":"10.1093\/humrep\/dew359"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jmig.2017.10.016","article-title":"A multicenter study evaluating the effect of ulipristal acetate during myomectomy","volume":"25","author":"Murji","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejogrb.2017.12.033","article-title":"Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy","volume":"222","author":"Brun","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0140","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/jum.14573","article-title":"Influence of ulipristal acetate therapy on uterine fibroid-related symptoms and on uterine and fibroid volumes and vascularity indices assessed by ultrasound","volume":"37","author":"Baggio","year":"2018","journal-title":"J Ultrasound Med"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5468\/ogs.2017.60.1.69","article-title":"Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist","volume":"60","author":"Lee","year":"2017","journal-title":"Obstet Gynecol Sci"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/01443615.2017.1287687","article-title":"An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (Esmya) including its effect on pre-menstrual syndrome","volume":"37","author":"Chen","year":"2017","journal-title":"J Obstet Gynaecol"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jogoh.2017.06.006","article-title":"Real-world data of 197 patients treated with ulipristal acetate for uterine fibroids: PREMYA study French population main outcomes","volume":"46","author":"Fernandez","year":"2017","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0160","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/CEOR.S139335","article-title":"Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women","volume":"9","author":"Chiumente","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jsbmb.2014.08.008","article-title":"Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors","volume":"144","author":"Petit-Topin","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0170","first-page":"325","article-title":"Ulipristal acetate (Ella): a selective progesterone receptor modulator for emergency contraception","volume":"36","author":"Kim","year":"2011","journal-title":"Pharm Ther"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0180","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/humrep\/det467","article-title":"Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo","volume":"29","author":"Barlow","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejogrb.2016.08.021","article-title":"Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study","volume":"205","author":"Ferrero","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0200","doi-asserted-by":"crossref","unstructured":"Donnez J, V\u00e1zquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101:1518\u201365.","DOI":"10.1016\/j.fertnstert.2014.02.008"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0210","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.07.1253","article-title":"First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids","volume":"102","author":"Luyckx","year":"2014","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0215","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0220","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/AOG.0000000000002942","article-title":"Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"132","author":"Liu","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0230","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/AOG.0000000000003211","article-title":"Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Lukes","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ijgo.12968","article-title":"Effect on surgical decisions: ulipristal acetate as key player in Belgian phase IV registration trial","volume":"147","author":"Verguts","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0240","doi-asserted-by":"crossref","unstructured":"Fauser BCJM, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One 2017;12:e0173523.","DOI":"10.1371\/journal.pone.0173523"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/aogs.13713","article-title":"Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): short-term results of a double-blind randomized controlled trial","volume":"99","author":"Milliano","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000505604","article-title":"Preoperative treatment with ulipristal acetate before outpatient hysteroscopic myomectomy","volume":"85","author":"Ferrero","year":"2020","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0255","first-page":"202","article-title":"Ulipristal acetate prior to in vitro fertilization in a female patient affected by uterine fibroids: a case report","volume":"20","author":"Lo Monte","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0260","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-606X.21.04731-X","article-title":"Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes","volume":"74","author":"Miriello","year":"2022","journal-title":"Minerva Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0265","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12958-020-00611-1","article-title":"Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids","volume":"18","author":"Morgante","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.fertnstert.2021.01.023","article-title":"Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial","volume":"116","author":"Osuga","year":"2021","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0275","first-page":"168","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"32","author":"Yousuf","year":"2023","journal-title":"Mymensingh Med J"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0280","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.fertnstert.2016.06.012","article-title":"Role of ethnicity in treating uterine fibroids with ulipristal acetate","volume":"106","author":"Murji","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0285","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejogrb.2018.01.020","article-title":"Ulipristal acetate for pre-operative management of uterine fibroids: modeling outcomes and costs","volume":"222","author":"Badiani","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2147\/CEOR.S143557","article-title":"Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis","volume":"9","author":"Geale","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0295","doi-asserted-by":"crossref","unstructured":"Fernandez H, Jourdain O, Villefranque V, Lehmann M, Lafuma A, Trancart M. Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France. BMJ Open 2017;7:e015571.","DOI":"10.1136\/bmjopen-2016-015571"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0300","doi-asserted-by":"crossref","first-page":"A510","DOI":"10.1016\/j.jval.2014.08.1563","article-title":"Economic evaluation of ulipristal acetate for the treatment of patients with moderate and severe symptoms of uterine fibroids in Romania","volume":"17","author":"Lorenzovici","year":"2014","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0305","first-page":"15","article-title":"Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation","volume":"68","author":"Maratea","year":"2016","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CEOR.S78115","article-title":"Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management","volume":"7","author":"Tsoi","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejogrb.2014.01.022","article-title":"The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids","volume":"175","author":"Nagy","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0320","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/13696998.2016.1254090","article-title":"Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis","volume":"20","author":"Zakiyah","year":"2017","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0325","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/uog.14668","article-title":"Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study","volume":"45","author":"Czuczwar","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejogrb.2015.06.018","article-title":"Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study","volume":"192","author":"Bizzarri","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0335","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jmig.2015.12.002","article-title":"Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study","volume":"23","author":"Ferrero","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13048-018-0420-1","article-title":"Comparison of the influence of three fibroid treatment options: supracervical hysterectomy, ulipristal acetate and uterine artery embolization on ovarian reserve \u2013 an observational study","volume":"11","author":"Czuczwar","year":"2018","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0345","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejogrb.2019.08.002","article-title":"Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: a pilot study","volume":"245","author":"Frijlingh","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jcpt.12590","article-title":"Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma","volume":"43","author":"Hrgovic","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0355","doi-asserted-by":"crossref","first-page":"756.e1","DOI":"10.1016\/j.ajog.2016.02.049","article-title":"Long-term nonsurgical control with ulipristal acetate of multiple uterine fibroids, enabling pregnancy","volume":"214","author":"Luyckx","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0360","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jogc.2015.11.004","article-title":"Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid","volume":"38","author":"Murad","year":"2016","journal-title":"J Obstet Gynaecol Canada"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0365","doi-asserted-by":"crossref","unstructured":"Monle\u00f3n J, Mart\u00ednez-Varea A, Galliano D, Pellicer A. Successful pregnancy after treatment with ulipristal acetate for uterine fibroids. Case Rep Obstet Gynecol 2014;2014:314587.","DOI":"10.1155\/2014\/314587"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0370","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jogoh.2019.03.015","article-title":"Disappearance of a myoma after pregnancy in a 38 years old patient, treated by ulipristal acetate without success before getting pregnant","volume":"48","author":"P\u00e9cout","year":"2019","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0375","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09513590.2018.1550062","article-title":"Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy \u2013 2 case studies","volume":"35","author":"Ciebiera","year":"2019","journal-title":"Gynecol Endocrinol l"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0380","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1933719118812720","article-title":"1,25 Dihydroxyvitamin D3 enhances the antifibroid effects of ulipristal acetate in human uterine fibroids","volume":"26","author":"Ali","year":"2019","journal-title":"Reprod Sci"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0385","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/humrep\/des221","article-title":"Ulipristal acetate does not impact human normal breast tissue","volume":"27","author":"Communal","year":"2012","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0390","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jmig.2017.02.025","article-title":"Does ulipristal acetate affect surgical experience at laparoscopic myomectomy?","volume":"24","author":"Luketic","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejogrb.2018.03.026","article-title":"Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate","volume":"224","author":"Yun","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"19","key":"10.1016\/j.ejogrb.2023.06.021_b0400","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.12998\/wjcc.v9.i19.5217","article-title":"Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: a case report and review of the literature","volume":"9","author":"Yang","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0405","doi-asserted-by":"crossref","unstructured":"Santoro A, Angelico G, Arciuolo D, et al. Failure of ulipristal acetate treatment as an indication for uterine malignancy: two case reports. Medicine 2018;97:e11532.","DOI":"10.1097\/MD.0000000000011532"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0410","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jogoh.2017.06.002","article-title":"Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma","volume":"46","author":"Kadhel","year":"2017","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0415","doi-asserted-by":"crossref","first-page":"236","DOI":"10.23736\/S2724-606X.23.05197-7","article-title":"Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms","volume":"75","author":"Kyeong","year":"2023","journal-title":"Minerva Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0420","first-page":"159","article-title":"Endometrial effects of prolonged therapy with the selective progesterone receptor modulator ulipristal acetate: a case report","volume":"61","author":"Levy","year":"2016","journal-title":"J Reprod Med"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0425","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/09513590.2017.1417376","article-title":"Ulipristal acetate for the management of acute heavy menstrual bleeding without fibroids","volume":"34","author":"Estadella","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0430","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rbmo.2020.11.012","article-title":"Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids","volume":"42","author":"Calderon","year":"2021","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09513590.2018.1505846","article-title":"Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids","volume":"35","author":"Conway","year":"2019","journal-title":"Gynecol Endocrinol"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0440","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jmig.2018.04.002","article-title":"Ulipristal acetate improves clinical symptoms in women with adenomyosis and uterine myomas","volume":"25","author":"Gracia","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0445","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/AOG.0000000000003112","article-title":"Ulipristal acetate for disseminated peritoneal leiomyomatosis","volume":"133","author":"Benlolo","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0450","doi-asserted-by":"crossref","unstructured":"Kortekaas KE, Pelikan HMP. Non-surgical intervention for retroperitoneal lymphogenic and pulmonary metastases of a benign leiomyoma: treatment with ulipristal acetate. BMJ Case Rep 2018;2018:bcr2017222693.","DOI":"10.1136\/bcr-2017-222693"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0455","doi-asserted-by":"crossref","unstructured":"Matytsina-Quinlan L, Matytsina L. Abnormal excessive per vagina (PV) bleeding on Esmya-selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid. BMJ Case Rep 2015;2015:bcr2014209015.","DOI":"10.1136\/bcr-2014-209015"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0460","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jmig.2016.08.004","article-title":"Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy treated 6 months with ulipristal acetate and contained power morcellation","volume":"24","author":"Istre","year":"2017","journal-title":"J Minim Invasive Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0465","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejogrb.2017.10.022","article-title":"Endometrial cancer after ulipristal acetate for uterine fibroma","volume":"219","author":"Ignatov","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0470","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/jog.13917","article-title":"Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and\/or adenomyosis","volume":"45","author":"Hong","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0475","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/PGP.0000000000000581","article-title":"Pathologic changes in uterine leiomyomas after extended treatment with ulipristal acetate","volume":"39","author":"Chang","year":"2020","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0480","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bcpt.13631","article-title":"Acute liver failure requiring transplantation: a possible link to ulipristal acetate treatment?","volume":"129","author":"Dinis\u2010Oliveira","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0485","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jhep.2020.11.041","article-title":"Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya","volume":"74","author":"Mozzanega","year":"2021","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ejogrb.2023.06.021_b0490","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40264-020-00975-8","article-title":"Liver injury with ulipristal acetate: exploring the underlying pharmacological basis","volume":"43","author":"Gatti","year":"2020","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0495","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.14309\/ajg.0000000000000756","article-title":"Acute liver failure associated with ulipristal acetate: a case report","volume":"115","author":"Carballo-Folgoso","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ejogrb.2023.06.021_b0500","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40264-020-00960-1","article-title":"An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with ulipristal acetate for the treatment of uterine fibroids","volume":"43","author":"Kang","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0505","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejogrb.2020.06.064","article-title":"Suspension of ulipristal acetate for uterine fibroids during ongoing EMA\u2019s review of liver injury risk: unfortunate timing during the Covid-19 pandemic!","volume":"252","author":"Rozenberg","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0510","doi-asserted-by":"crossref","unstructured":"EMA suspends licence for ulipristal acetate for uterine fibroids. Drug Ther Bull 2020;58:70.","DOI":"10.1136\/dtb.2020.000022"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0515","first-page":"98","article-title":"Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements","volume":"110","author":"Indraccolo","year":"2019","journal-title":"Recenti Prog Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0520","doi-asserted-by":"crossref","unstructured":"Ulipristal acetate (Esmya): restrictions on use. Drug Ther Bull 2018;56:127.","DOI":"10.1136\/dtb.2018.11.000033"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0525","first-page":"2020","article-title":"Ulipristal acetate for uterine fibroids: EMA recommends restricting use","volume":"31","author":"Prac","year":"2021","journal-title":"European Medicines Agency"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0530","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2016.10.012","article-title":"Medical or surgical management of fibroids? An internet survey of gynecologists\u2019 views","volume":"95","author":"Pazzaglia","year":"2017","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0535","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/09513590.2019.1680626","article-title":"Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience","volume":"36","author":"Del Forno","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1091520","article-title":"Therapy with ulipristal acetate in a hypertensive patient","volume":"2018","author":"Alcalde Dominguez","year":"2018","journal-title":"Case Rep Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/3249268","article-title":"Ulipristal acetate efficacy in a patient with symptomatic fibroid and concomitant pulmonary embolism","volume":"2020","author":"von Wunster","year":"2020","journal-title":"Case Rep Med"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0550","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/09513590.2019.1707795","article-title":"Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases","volume":"36","author":"Palaia","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0555","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejogrb.2018.06.027","article-title":"Changes in sexuality during ulipristal acetate treatment in women with symptomatic uterine fibroids","volume":"228","author":"Tuschy","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0560","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09513590.2019.1640202","article-title":"Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis","volume":"36","author":"Biscione","year":"2020","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0565","first-page":"1439","article-title":"Myoma migration: an unexpected \u2018effect\u2019 with ulipristal acetate treatment","volume":"20","author":"Willame","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0570","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/01443615.2022.2111516","article-title":"Ultrasonographic appearance of the endometrium after saline infusion in women presenting with PRM-associated endometrial changes, due to the use of ulipristal acetate","volume":"42","author":"Cosyns","year":"2022","journal-title":"J Obstet Gynaecol J Inst Obstet Gynaecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0575","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/PGP.0000000000000450","article-title":"Endometrial changes in surgical specimens of perimenopausal patients treated with ulipristal acetate for uterine leiomyomas","volume":"37","author":"Nogales","year":"2018","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0580","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.prp.2016.10.010","article-title":"Histomorphological changes in endometriosis in a patient treated with ulipristal: a case report","volume":"213","author":"Bateman","year":"2017","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0585","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejogrb.2018.11.009","article-title":"Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: exploratory findings at a tertiary referral center","volume":"232","author":"Gracia","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0590","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jmig.2016.01.010","article-title":"Hysteroscopic patterns in women on treatment with ulipristal acetate 5 mg\/day: a preliminary study","volume":"23","author":"Bettocchi","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0595","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13645706.2020.1829648","article-title":"Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study","volume":"31","author":"De Franciscis","year":"2022","journal-title":"Minim Invasive Ther Allied Technol"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0600","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.rbmo.2018.12.013","article-title":"Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium","volume":"38","author":"Kolanska","year":"2019","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0605","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.fertnstert.2021.02.008","article-title":"The endometrial response to modulation of ligand-progesterone receptor pathways is reversible","volume":"116","author":"Chodankar","year":"2021","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.ejogrb.2023.06.021_b0610","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14737159.2021.1941878","article-title":"Dual agonist-antagonist effect of ulipristal acetate in human endometrium and myometrium","volume":"21","author":"Salas","year":"2021","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0615","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.rbmo.2018.04.050","article-title":"Gene expression changes in uterine myomas in response to ulipristal acetate treatment","volume":"37","author":"Courtoy","year":"2018","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0620","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.fertnstert.2017.11.023","article-title":"Ulipristal acetate decreases transforming growth factor \u03b23 serum and tumor tissue concentrations in patients with uterine fibroids","volume":"109","author":"Ciebiera","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0625","doi-asserted-by":"crossref","unstructured":"Courtoy GE, Henriet P, Marbaix E, et al. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metab 2018;103:1566\u201373.","DOI":"10.1210\/jc.2017-02295"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0630","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1159\/000480011","article-title":"Progesterone receptor isoforms, nuclear corepressor-1 and steroid receptor coactivator-1 and B-cell lymphoma 2 and Akt and Akt phosphorylation status in uterine myomas after ulipristal acetate treatment: a systematic immunohistochemical evaluation","volume":"83","author":"Courtoy","year":"2018","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0635","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejogrb.2015.05.022","article-title":"Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist","volume":"191","author":"Yun","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0640","doi-asserted-by":"crossref","unstructured":"Courtoy GE, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015;10:426\u201334.e1.","DOI":"10.1016\/j.fertnstert.2015.04.025"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0645","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1933719117728802","article-title":"Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial","volume":"25","author":"Cox","year":"2018","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0650","first-page":"1127","article-title":"UPA effects on endometrium \u2013 what is the significance?","volume":"59","author":"Ple\u015f","year":"2018","journal-title":"Rom J Morphol Embryol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0655","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.fertnstert.2019.08.090","article-title":"Steroid hormones and hormone antagonists regulate the neural marker neurotrimin in uterine leiomyoma","volume":"113","author":"Parikh","year":"2020","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0660","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1933719118816836","article-title":"Ulipristal acetate mediates decreased proteoglycan expression through regulation of nuclear factor of activated T-cells (NFAT5)","volume":"26","author":"Britten","year":"2019","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0665","doi-asserted-by":"crossref","unstructured":"Small B, Millard CEF, Kisanga EP, et al. The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor. J Clin Endocrinol Metab 2020;105:716\u201334.","DOI":"10.1210\/clinem\/dgz139"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0670","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1933719114542019","article-title":"Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells","volume":"21","author":"Ciarmela","year":"2014","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00350","article-title":"Ulipristal acetate interferes with actin remodeling induced by 17\u03b2-estradiol and progesterone in human endometrial stromal cells","volume":"9","author":"Shortrede","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0680","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2018.3779","article-title":"Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix","author":"Shin","year":"2018","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0685","doi-asserted-by":"crossref","unstructured":"Ng SSM, Jorge S, Malik M, et al. A-kinase anchoring protein 13 (AKAP13) augments progesterone signaling in uterine fibroid cells. J Clin Endocrinol Metab 2019;104:970\u201380.","DOI":"10.1210\/jc.2018-01216"},{"issue":"12","key":"10.1016\/j.ejogrb.2023.06.021_b0690","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.7150\/ijms.75203","article-title":"The potential of transforming growth factor-beta inhibitor and vascular endothelial growth factor inhibitor as therapeutic agents for uterine leiomyoma","volume":"19","author":"Park","year":"2022","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0695","doi-asserted-by":"crossref","unstructured":"Lewis TD, Malik M, Britten J, Parikh T, Cox J, Catherino WH. Ulipristal acetate decreases active TGF-\u03b23 and its canonical signaling in uterine leiomyoma via two novel mechanisms. Fertil Steril 2019;111:806\u201315.e1.","DOI":"10.1016\/j.fertnstert.2018.12.026"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0700","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.fertnstert.2019.08.007","article-title":"Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study","volume":"112","author":"Del Bello","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0705","first-page":"4","article-title":"Proteins involved in oxidative stress in leiomyoma tissues treated with ulipristal acetate","volume":"23","author":"Ura","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0710","doi-asserted-by":"crossref","unstructured":"Kanda R, Miyagawa Y, Wada-Hiraike O, et al. Ulipristal acetate simultaneously provokes antiproliferative and proinflammatory responses in endometrial cancer cells. Heliyon 2022;8:e08696.","DOI":"10.1016\/j.heliyon.2021.e08696"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0715","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/jcm10040562","article-title":"Markers of cellular proliferation, apoptosis, estrogen\/progesterone receptor expression and fibrosis in selective progesterone receptor modulator (ulipristal acetate)-treated uterine fibroids","volume":"10","author":"Szyd\u0142owska","year":"2021","journal-title":"J Clin Med"},{"issue":"19","key":"10.1016\/j.ejogrb.2023.06.021_b0720","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.3390\/jcm10194442","article-title":"Ulipristal acetate modifies miRNA expression in both superficial and basal layers of the human endometrium","volume":"10","author":"Kolanska","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0725","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1038\/s41598-021-88346-w","article-title":"Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats","volume":"11","author":"Hamza","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0730","doi-asserted-by":"crossref","unstructured":"Kolterud \u00c5, V\u00e4lim\u00e4ki N, Kuisma H, et al. Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate. Hum Mol Genet 2023;32:1063\u201371.","DOI":"10.1093\/hmg\/ddac217"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0735","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/09513590.2021.1929152","article-title":"Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up","volume":"37","author":"Nicol\u00e1s","year":"2021","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0740","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3390\/jcm10163721","article-title":"Markers of inflammation and vascular parameters in selective progesterone receptor modulator (ulipristal acetate)-treated uterine fibroids","volume":"10","author":"Szyd\u0142owska","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0745","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.18632\/oncotarget.21378","article-title":"Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling","volume":"9","author":"Singhal","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0750","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53467-w","article-title":"EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model","volume":"9","author":"Nair","year":"2019","journal-title":"Sci Rep"},{"issue":"10-13","key":"10.1016\/j.ejogrb.2023.06.021_b0755","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.steroids.2003.09.008","article-title":"Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy","volume":"68","author":"DeManno","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0760","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0039-128X(00)00178-1","article-title":"Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity","volume":"65","author":"Elger","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0765","doi-asserted-by":"crossref","unstructured":"Stewart EA, Diamond MP, Williams ARW, et al. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Hum Reprod 2019;34:623\u201334.","DOI":"10.1093\/humrep\/dez007"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0770","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0775","doi-asserted-by":"crossref","unstructured":"Xu Q, Ohara N, Liu J, Nakabayashi K, et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Metab 2007;293:E1002\u201311.","DOI":"10.1152\/ajpendo.00210.2007"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0780","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2005-2379","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial Cells","volume":"91","author":"Chen","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0785","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/humrep\/den025","article-title":"Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer","volume":"23","author":"Morikawa","year":"2008","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0790","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1210\/jc.2006-0898","volume":"92","author":"Sasaki","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"S8","key":"10.1016\/j.ejogrb.2023.06.021_b0795","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1933719107311464","article-title":"Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells","volume":"14","author":"Ohara","year":"2007","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0800","doi-asserted-by":"crossref","unstructured":"Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGF\u03b23 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006;21:1869\u201377.","DOI":"10.1093\/humrep\/del035"},{"issue":"12","key":"10.1016\/j.ejogrb.2023.06.021_b0805","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0810","doi-asserted-by":"crossref","unstructured":"Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696\u2013704.","DOI":"10.1093\/humrep\/dem026"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0815","doi-asserted-by":"crossref","unstructured":"Diamond MP, Stewart EA, Williams ARW, et al. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids. Hum Reprod Open 2019;2019:2679\u201383.","DOI":"10.1093\/hropen\/hoz027"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0820","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcph.998","article-title":"Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women","volume":"58","author":"Sch\u00fctt","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0825","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.fertnstert.2018.10.033","article-title":"Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids","volume":"111","author":"Magnay","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0830","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.05.043","article-title":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2","volume":"252","author":"Gemzell-Danielsson","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.ejogrb.2023.06.021_b0835","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bcp.15014","article-title":"Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure\u2013response modelling and simulation","volume":"88","author":"Sutter","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0840","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","article-title":"Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study","volume":"111","author":"Bradley","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0845","first-page":"553","article-title":"GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review","volume":"58","author":"De Falco","year":"2006","journal-title":"Minerva Ginecol"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b0850","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/13543784.2021.1957830","article-title":"Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas","volume":"30","author":"Dababou","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"10356","key":"10.1016\/j.ejogrb.2023.06.021_b0855","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(22)01475-1","article-title":"Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials","volume":"400","author":"Donnez","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0860","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm200216q","article-title":"Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- d ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonad","volume":"54","author":"Miwa","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0865","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","article-title":"Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial","volume":"21","author":"Hoshiai","year":"2021","journal-title":"BMC Womens Health"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0870","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0875","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/14656566.2022.2030705","article-title":"An evaluation of relugolix\/estradiol\/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women","volume":"23","author":"Ali","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0880","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/AOG.0000000000004988","article-title":"Long-term relugolix combination therapy for symptomatic uterine leiomyomas","volume":"140","author":"Al-Hendy","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0885","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000004787","article-title":"Relugolix combination therapy for uterine leiomyoma-associated pain in the LIBERTY randomized trials","volume":"139","author":"Stewart","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0890","doi-asserted-by":"crossref","unstructured":"Stewart EA, Lukes AS, Venturella R, et al. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol 2023;228:320.e1\u201311.","DOI":"10.1016\/j.ajog.2022.11.1278"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0895","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0900","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0905","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/jog.15269","article-title":"Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: a retrospective comparative study with leuprorelin injection","volume":"48","author":"Takeda","year":"2022","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0910","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1111\/jog.14479","article-title":"Prolapse of a pedunculated uterine leiomyoma through the cervix during GnRH antagonist treatment: case report and literature review","volume":"46","author":"Ishizawa","year":"2020","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0915","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.xfss.2022.01.004","article-title":"Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures","volume":"3","author":"Wright","year":"2022","journal-title":"F&S Sci"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0920","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-021-01442-x","article-title":"A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy","volume":"21","author":"Sasamori","year":"2021","journal-title":"BMC Womens Health"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0925","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/17512433.2021.1900726","article-title":"Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women","volume":"14","author":"Ali","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0930","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.ajog.2020.07.032","article-title":"Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids","volume":"224","author":"Al-Hendy","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.ejogrb.2023.06.021_b0935","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1111\/bcp.15440","article-title":"Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids","volume":"88","author":"Beck","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ejogrb.2023.06.021_b0940","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0945","doi-asserted-by":"crossref","unstructured":"Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril 2017;108:152\u201360.e4.","DOI":"10.1016\/j.fertnstert.2017.05.006"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0950","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.xfre.2021.05.004","article-title":"Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis","volume":"2","author":"Muneyyirci-Delale","year":"2021","journal-title":"F&S Rep"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b0955","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b0960","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b0965","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-020-00921-y","article-title":"Drug\u2013drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy","volume":"60","author":"Nader","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b0970","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ijgo.13611","article-title":"The effect of N-acetyl cysteine on the volume of uterine leiomyoma: a randomized clinical trial","volume":"154","author":"Aghaamoo","year":"2021","journal-title":"Int J Gynecol Obstet"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b0975","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.fertnstert.2018.07.024","article-title":"Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production","volume":"110","author":"Malik","year":"2018","journal-title":"Fertil Steril"},{"issue":"51","key":"10.1016\/j.ejogrb.2023.06.021_b0980","doi-asserted-by":"crossref","first-page":"35075","DOI":"10.1074\/jbc.M114.583575","article-title":"Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells","volume":"289","author":"Borahay","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0985","doi-asserted-by":"crossref","unstructured":"Afrin S, El Sabeh M, Islam MS, et al. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res 2021;172:105856.","DOI":"10.1016\/j.phrs.2021.105856"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0990","doi-asserted-by":"crossref","unstructured":"Afrin S, El Sabeh M, Miyashita-Ishiwata M, Charewycz N, Singh B, Borahay MA. Simvastatin reduces plasma membrane caveolae and caveolin-1 in uterine leiomyomas. Life Sci 2022;304:120708.","DOI":"10.1016\/j.lfs.2022.120708"},{"key":"10.1016\/j.ejogrb.2023.06.021_b0995","doi-asserted-by":"crossref","unstructured":"El Sabeh M, Saha SK, Afrin S, Borahay MA. Simvastatin inhibits Wnt\/\u03b2-catenin pathway in uterine leiomyoma. Endocrinology 2021;162:bqab211.","DOI":"10.1210\/endocr\/bqab211"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1000","doi-asserted-by":"crossref","unstructured":"Borahay MA, Vincent K, Motamedi M, et al. Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol 2015;213:196.e1\u20138.","DOI":"10.1016\/j.ajog.2015.03.055"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b1005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jcmm.17211","article-title":"Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-\u03b23 and Wnt\/\u03b2-catenin pathways","volume":"26","author":"Afrin","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1010","doi-asserted-by":"crossref","unstructured":"Afrin S, Islam MS, Patzkowsky K, et al. Simvastatin ameliorates altered mechanotransduction in uterine leiomyoma cells. Am J Obstet Gynecol 2020;223:733.e1\u201314.","DOI":"10.1016\/j.ajog.2020.05.012"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1015","doi-asserted-by":"crossref","unstructured":"Jayes FL, Liu B, Feng L, Aviles-Espinoza N, Leikin S, Leppert PC. Evidence of biomechanical and collagen heterogeneity in uterine fibroids. PLoS One 2019;14:e0215646.","DOI":"10.1371\/journal.pone.0215646"},{"issue":"596","key":"10.1016\/j.ejogrb.2023.06.021_b1020","first-page":"e1","article-title":"Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum","volume":"215","author":"Jayes","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b1025","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s43032-021-00573-8","article-title":"A phase I clinical trial to assess safety and tolerability of injectable collagenase in women with symptomatic uterine fibroids","volume":"28","author":"Singh","year":"2021","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1030","doi-asserted-by":"crossref","unstructured":"Islam MS, Afrin S, Singh B, et al. Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. Clin Transl Med 2021;11:e475.","DOI":"10.1002\/ctm2.475"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1035","doi-asserted-by":"crossref","unstructured":"Yager JD. Catechol-O-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug Discov Today Dis Mech 2012;9:e41\u20136.","DOI":"10.1016\/j.ddmec.2012.10.002"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b1040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.fertnstert.2005.12.049","article-title":"Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas","volume":"86","author":"Salama","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1045","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1093\/humrep\/der280","article-title":"Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model","volume":"26","author":"Hassan","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1050","first-page":"95","article-title":"The effect of vitamin D deficiency on overgrowth of uterine fibroids: a blinded randomized clinical trial","volume":"15","author":"Tanha","year":"2021","journal-title":"Int J Fertil Steril"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b1055","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.fertnstert.2009.08.065","article-title":"Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells","volume":"94","author":"Zhang","year":"2010","journal-title":"Fertil Steril"},{"issue":"7","key":"10.1016\/j.ejogrb.2023.06.021_b1060","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41401-018-0184-6","article-title":"Hypovitaminosis D exacerbates the DNA damage load in human uterine fibroids, which is ameliorated by vitamin D3 treatment","volume":"40","author":"Ali","year":"2019","journal-title":"Acta Pharmacol Sin"},{"issue":"16","key":"10.1016\/j.ejogrb.2023.06.021_b1065","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.3390\/nu14163371","article-title":"Immunohistochemical expression of vitamin d receptor in uterine fibroids","volume":"14","author":"Markowska","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/IJWH.S163961","article-title":"Diet-induced vitamin D deficiency triggers inflammation and DNA damage profile in murine myometrium","volume":"10","author":"ElHusseini","year":"2018","journal-title":"Int J Womens Health"},{"issue":"6","key":"10.1016\/j.ejogrb.2023.06.021_b1075","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3390\/cells9061459","article-title":"Vitamin D3 ameliorates DNA damage caused by developmental exposure to endocrine disruptors in the uterine myometrial stem cells of Eker rats","volume":"9","author":"Elkafas","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b1080","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00404-020-05825-7","article-title":"CYP24A1 expression analysis in uterine leiomyoma regarding MED12 mutation profile","volume":"303","author":"Fazeli","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejogrb.2018.08.018","article-title":"Human uterine leiomyoma contains low levels of 1, 25 dihdroxyvitamin D3, and shows dysregulated expression of vitamin D metabolizing enzymes","volume":"229","author":"Othman","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13224-018-1195-4","article-title":"Vitamin D3 level in women with uterine fibroids: an observational study in Eastern Indian population","volume":"69","author":"Singh","year":"2019","journal-title":"J Obstet Gynecol India"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b1095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5582\/ddt.2021.01019","article-title":"Association between serum vitamin D level and uterine fibroid in premenopausal women in Indian population","volume":"16","author":"Kumari","year":"2022","journal-title":"Drug Discov Ther"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b1100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/01443615.2019.1654986","article-title":"Evaluation of 25-hydroxy vitamin D3 levels in patients with a fibroid uterus","volume":"40","author":"Srivastava","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1105","first-page":"93","article-title":"Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study","volume":"5","author":"Sabry","year":"2013","journal-title":"Int J Womens Health"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b1110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09513590.2017.1391774","article-title":"25-Hydroxy vitamin D levels in premenopausal Turkish women with uterine leiomyoma","volume":"34","author":"Oskovi Kaplan","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b1115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.fertnstert.2010.07.1041","article-title":"Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase","volume":"95","author":"Sharan","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1095\/biolreprod.111.098145","article-title":"1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model","volume":"86","author":"Halder","year":"2012","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1125","doi-asserted-by":"crossref","unstructured":"Al-Hendy A, Diamond MP, El-Sohemy A, Halder SK. 1,25-Dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells. J Clin Endocrinol Metab 2015;100:E572\u201382.","DOI":"10.1210\/jc.2014-4011"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b1130","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/humrep\/det265","article-title":"Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells","volume":"28","author":"Halder","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1135","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1095\/biolreprod.113.107714","article-title":"1,25-dihydroxyvitamin D3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells","volume":"89","author":"Halder","year":"2013","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1140","doi-asserted-by":"crossref","unstructured":"Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2011;96:E754\u201362.","DOI":"10.1210\/jc.2010-2131"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1145","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1210\/jc.2015-3555","article-title":"Vitamin D3 inhibits Wnt\/\u03b2-catenin and mTOR signaling pathways in human uterine fibroid cells","volume":"101","author":"Al-Hendy","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejogrb.2023.06.021_b1150","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.xfss.2021.04.002","article-title":"A-kinase anchoring protein 13 interacts with the vitamin D receptor to alter vitamin D-dependent gene activation in uterine leiomyoma cells","volume":"2","author":"Cross","year":"2021","journal-title":"F&S Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1155","first-page":"125","article-title":"The effect of vitamin D supplementation on the size of uterine leiomyoma in women with vitamin D deficiency","volume":"10","author":"Hajhashemi","year":"2019","journal-title":"Casp J Intern Med"},{"issue":"1","key":"10.1016\/j.ejogrb.2023.06.021_b1160","first-page":"53","article-title":"Effect of vitamin D3 supplementation on symptomatic uterine leiomyoma in women with hypovitaminosis D","volume":"12","author":"Suneja","year":"2021","journal-title":"J Midlife Health"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1165","doi-asserted-by":"crossref","unstructured":"Ciavattini A, Delli Carpini G, Serri M, et al. Hypovitaminosis D and \u2018small burden\u2019 uterine fibroids. Medicine 2016;95:e5698.","DOI":"10.1097\/MD.0000000000005698"},{"issue":"5","key":"10.1016\/j.ejogrb.2023.06.021_b1170","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.fertnstert.2008.02.136","article-title":"Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro","volume":"91","author":"Bl\u00e4uer","year":"2009","journal-title":"Fertil Steril"},{"issue":"9","key":"10.1016\/j.ejogrb.2023.06.021_b1175","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1933719114537721","article-title":"Paricalcitol, a vitamin D receptor activator, inhibits tumor formation in a murine model of uterine fibroids","volume":"21","author":"Halder","year":"2014","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09513590.2021.1991909","article-title":"Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study","volume":"38","author":"Grandi","year":"2022","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijgo.13692","article-title":"Nutraceuticals in fibroid management after ulipristal acetate administration: an observational study on patients\u2019 compliance","volume":"156","author":"Tinelli","year":"2022","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1190","first-page":"477","article-title":"Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study","volume":"5","author":"Roshdy","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1195","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00404-020-05907-6","article-title":"Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study","volume":"303","author":"Biro","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1200","doi-asserted-by":"crossref","unstructured":"Zhang D, Al-Hendy M, Richard-Davis G, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010;202:289.e1\u20139.","DOI":"10.1016\/j.ajog.2009.10.885"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000363410","article-title":"Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase","volume":"78","author":"Zhang","year":"2014","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1210","first-page":"1","article-title":"Biological and mechanistic characterization of novel prodrugs of green tea polyphenol epigallocatechin gallate analogs in human leiomyoma cell lines","volume":"13","author":"Saber","year":"2016","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.01105","article-title":"Gyejibongnyeong-hwan (gui zhi fu ling wan) ameliorates human uterine myomas via apoptosis","volume":"10","author":"Lee","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114676","article-title":"Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids","volume":"283","author":"Meng","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1225","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jep.2015.05.038","article-title":"Prescription patterns of Chinese herbal products for patients with uterine fibroid in Taiwan: a nationwide population-based study","volume":"171","author":"Yen","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6882-14-2","article-title":"Chinese herbal medicine Guizhi Fuling formula for treatment of uterine fibroids: a systematic review of randomised clinical trials","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1235","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1142\/S0192415X92000333","article-title":"Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas","volume":"20","author":"Sakamoto","year":"1992","journal-title":"Am J Chin Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1240","first-page":"943","article-title":"Anti-uterine fibroid effect of standardized Labisia Pumila Var. Alata extracts in vitro and in human uterine fibroid cancer xenograft model. Asian Pacific","volume":"21","author":"Zakaria","year":"2020","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1245","first-page":"157","article-title":"A brief review on resveratrol","author":"Malviya","year":"2022","journal-title":"Asian J Res Pharm Sci"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/antiox8040099","article-title":"Natural antioxidant resveratrol suppresses uterine fibroid cell growth and extracellular matrix formation in vitro and in vivo","volume":"8","author":"Chen","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1255","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.fct.2018.07.030","article-title":"Resveratrol inhibits human leiomyoma cell proliferation via crosstalk between integrin \u03b1v\u03b23 and IGF-1R","volume":"120","author":"Ho","year":"2018","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1260","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.foodchem.2017.02.096","article-title":"Impact of germination on nutritional and physicochemical properties of adlay seed (Coixlachryma-jobi L.)","volume":"229","author":"Xu","year":"2017","journal-title":"Food Chem"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1265","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2225-4110(16)30112-2","article-title":"Adlay (\u858f\u82e1 y\u00ec y\u012d, \u2018soft-shelled job\u2019s tears\u2019; the seeds of Coix lachryma-jobi L. var. ma-yuen Stapf) is a potential cancer chemopreventive agent toward multistage carcinogenesis processes","volume":"2","author":"Kuo","year":"2012","journal-title":"J Tradit Complement Med"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1270","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/jsfa.4393","article-title":"Effects of adlay seed oil on blood lipids and antioxidant capacity in hyperlipidemic rats","volume":"91","author":"Yu","year":"2011","journal-title":"J Sci Food Agric"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1275","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.bbrc.2012.11.058","article-title":"A polysaccharide fraction of adlay seed (Coixlachryma-jobi L.) induces apoptosis in human non-small cell lung cancer A549 cells","volume":"430","author":"Lu","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1280","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3390\/molecules24081556","article-title":"Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf.) hull extract and active compounds inhibit proliferation of primary human leiomyoma cells and protect against sexual hormone-induced mice smooth muscle hyperproliferation","volume":"24","author":"Lin","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1285","first-page":"1","article-title":"Medicinal potentials of Orthosiphon stamineus Benth","volume":"1","author":"Basheer","year":"2010","journal-title":"Webmed Cent"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1290","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jmf.2011.1973","article-title":"Orthosiphon stamineus: traditional uses, phytochemistry, pharmacology, and toxicology","volume":"15","author":"Ameer","year":"2012","journal-title":"J Med Food"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1295","first-page":"2737","article-title":"Orthosiphon stamineus extracts inhibits proliferation and induces apoptosis in uterine fibroid cells","volume":"19","author":"Pauzi","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5115\/acb.2017.50.3.219","article-title":"Protective effect of Rhus verniciflua Stokes extract in an experimental model of post-menopausal osteoporosis","volume":"50","author":"Jeong","year":"2017","journal-title":"Anat Cell Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5115\/acb.2016.49.3.189","article-title":"Rhus verniciflua Stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation","volume":"49","author":"Gil","year":"2016","journal-title":"Anat Cell Biol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1310","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1038\/s41598-020-64871-y","article-title":"Fisetin induces apoptosis in uterine leiomyomas through multiple pathways","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1315","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2174\/138955711795305335","article-title":"A review on the dietary flavonoid kaempferol","volume":"11","author":"Calderon-Montano","year":"2011","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1320","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.12659\/MSM.898127","article-title":"Mechanistic study of the inhibitory effect of kaempferol on uterine fibroids in vitro","volume":"22","author":"Li","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1325","doi-asserted-by":"crossref","first-page":"15781","DOI":"10.3390\/molecules200915781","article-title":"Chemical composition, antioxidative and anticancer activities of the essential oil: curcumae rhizoma\u2013Sparganii rhizoma, a traditional herb pair","volume":"20","author":"Xu","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2019.112465","article-title":"Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae rhizoma-Sparganii rhizoma and the single herbs","volume":"250","author":"Chang","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1335","first-page":"9","article-title":"Ameliorative effects of component Chinese medicine from Curcumae rhizoma and Sparganii rhizoma, a traditional herb pair, on uterine leiomyoma in a rat model","author":"Zhang","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1340","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.650022","article-title":"Inhibition of fibroblast activation in uterine leiomyoma by components of rhizoma Curcumae and rhizoma Sparganii","volume":"9","author":"Feng","year":"2021","journal-title":"Front Publ Health"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1345","doi-asserted-by":"crossref","unstructured":"Yu CH, Zhao JS, Zhao H, et al. Transcriptional profiling of uterine leiomyoma rats treated by a traditional herb pair, Curcumae rhizoma and Sparganii rhizoma. Brazilian J Med Biol Res 2019;52:e8132.","DOI":"10.1590\/1414-431x20198132"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116311","article-title":"Curcumol, a major terpenoid from Curcumae rhizoma, attenuates human uterine leiomyoma cell development via the p38MAPK\/NF-\u03baB pathway","volume":"310","author":"Yu","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1355","series-title":"DC Dutta's textbook of gynecology","author":"Konar","year":"2013"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1360","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/humrep\/12.9.2028","article-title":"Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix","volume":"12","author":"Gonzalez-Barcena","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1365","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0015-0282(02)04913-0","article-title":"Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia","volume":"79","author":"Xiao","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1370","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2009.09.048","article-title":"Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes","volume":"94","author":"Murat Naki","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2023.06.021_b1375","doi-asserted-by":"crossref","unstructured":"Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165\u201373.e4.","DOI":"10.1016\/j.fertnstert.2015.09.032"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211523002634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211523002634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:03:10Z","timestamp":1759557790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211523002634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":275,"alternative-id":["S0301211523002634"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.06.021","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary approaches in the management of uterine leiomyomas","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}